Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 5
1989 11
1990 39
1991 43
1992 38
1993 66
1994 86
1995 95
1996 90
1997 72
1998 103
1999 77
2000 63
2001 48
2002 45
2003 53
2004 42
2005 56
2006 50
2007 48
2008 45
2009 47
2010 58
2011 49
2012 66
2013 87
2014 67
2015 51
2016 70
2017 53
2018 48
2019 50
2020 39
2021 40
2022 35
2023 38
2024 29
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,866 results

Results by year

Filters applied: . Clear all
Page 1
Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?
Doggrell SA. Doggrell SA. Expert Opin Pharmacother. 2017 Jul;18(10):1019-1026. doi: 10.1080/14656566.2017.1342809. Epub 2017 Jun 19. Expert Opin Pharmacother. 2017. PMID: 28612633 Review.
Area covered: In an attempt to maintain plasma levels of granisetron during the delayed phase of CINV, longer-acting preparations of granisetron have been manufactured. ...At present, it seems likely that there will be ongoing roles for intravenous and subcutaneous …
Area covered: In an attempt to maintain plasma levels of granisetron during the delayed phase of CINV, longer-acting preparations of …
Granisetron: is there a dose-response effect on nausea and vomiting?
Minami M. Minami M. Cancer Chemother Pharmacol. 2003 Aug;52(2):89-98. doi: 10.1007/s00280-003-0652-6. Epub 2003 May 29. Cancer Chemother Pharmacol. 2003. PMID: 12783208 Review.
The aim of this article is to examine the hypothesis that there is a dose-response effect of granisetron for preventing chemotherapy-induced nausea and vomiting in cancer patients. METHODS: A literature review of relevant publications was undertaken to provide a comprehens …
The aim of this article is to examine the hypothesis that there is a dose-response effect of granisetron for preventing chemotherapy- …
Transdermal granisetron.
Duggan ST, Curran MP. Duggan ST, et al. Drugs. 2009;69(18):2597-605. doi: 10.2165/11202780-000000000-00000. Drugs. 2009. PMID: 19943709 Review.
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive …
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomitin …
Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting.
Spartinou A, Nyktari V, Papaioannou A. Spartinou A, et al. Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1289-1297. doi: 10.1080/17425255.2017.1396317. Epub 2017 Oct 27. Expert Opin Drug Metab Toxicol. 2017. PMID: 29057666 Review.
Areas covered: In this review the authors provide a detailed description of granisetron's chemistry pharmacokinetics, pharmacodynamics, toxicity and a brief review of clinical trials involving granisetron and the management of CINV. ...Expert opinion: According to c …
Areas covered: In this review the authors provide a detailed description of granisetron's chemistry pharmacokinetics, pharmacodynamic …
Granisetron: an update on its clinical use in the management of nausea and vomiting.
Aapro M. Aapro M. Oncologist. 2004;9(6):673-86. doi: 10.1634/theoncologist.9-6-673. Oncologist. 2004. PMID: 15561811 Free article. Review.
Extensive clinical trial data have shown granisetron to be an effective and well-tolerated agent for the treatment of nausea and vomiting in the oncology and surgical settings. Granisetron has also been shown to be effective and well tolerated in special populations …
Extensive clinical trial data have shown granisetron to be an effective and well-tolerated agent for the treatment of nausea and vomi …
Granisetron protects polymicrobial sepsis-induced acute lung injury in mice.
Wang J, Gong S, Wang F, Niu M, Wei G, He Z, Gu T, Jiang Y, Liu A, Chen P. Wang J, et al. Biochem Biophys Res Commun. 2019 Jan 22;508(4):1004-1010. doi: 10.1016/j.bbrc.2018.12.031. Epub 2018 Dec 11. Biochem Biophys Res Commun. 2019. PMID: 30551881 Free article.
Sepsis is a serious condition with a high mortality rate worldwide. Granisetron is an anti-nausea drug for patients undergoing chemotherapy. Here we aimed to identify the novel effect of granisetron on sepsis-induced acute lung injury (ALI). Our results showed that …
Sepsis is a serious condition with a high mortality rate worldwide. Granisetron is an anti-nausea drug for patients undergoing chemot …
Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
Hsu YC, Chen CY, Tam KW, Hsu CY. Hsu YC, et al. Eur J Clin Pharmacol. 2021 Nov;77(11):1597-1609. doi: 10.1007/s00228-021-03157-2. Epub 2021 May 15. Eur J Clin Pharmacol. 2021. PMID: 33993343
Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Therefore, we conducted a meta-analysis to evaluate the effectiveness of palonosetron versus granisetron in p …
Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron …
Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL, Benfield P. Plosker GL, et al. Pharmacoeconomics. 1996 Apr;9(4):357-74. doi: 10.2165/00019053-199609040-00009. Pharmacoeconomics. 1996. PMID: 10160110 Review.
Like other 5-HT3 receptor antagonists, granisetron is generally well tolerated by most patients and its antiemetic efficacy is enhanced when used concomitantly with dexamethasone. ...Other economic evaluations suggest that granisetron may be more cost effective than …
Like other 5-HT3 receptor antagonists, granisetron is generally well tolerated by most patients and its antiemetic efficacy is enhanc …
Granisetron.
Nodoushani M. Nodoushani M. Conn Med. 1995 Apr;59(4):209-11. Conn Med. 1995. PMID: 7606907 Review. No abstract available.
Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.
Feyer P, Seegenschmiedt MH, Steingraeber M. Feyer P, et al. Support Care Cancer. 2005 Sep;13(9):671-8. doi: 10.1007/s00520-004-0766-3. Epub 2005 Jul 26. Support Care Cancer. 2005. PMID: 16044252 Review.
Current treatment guidelines recommend the use of 5-HT(3) receptor antagonists with or without corticosteroids for highly and moderately emetogenic radiotherapy, though only granisetron and ondansetron are currently indicated for RINV in most countries. Granisetron …
Current treatment guidelines recommend the use of 5-HT(3) receptor antagonists with or without corticosteroids for highly and moderately eme …
1,866 results